

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Jun 2026

### A randomized placebo-controlled trial to determine the effect of iron supplementation on hematological indices in pregnant women with hemoglobin $\geq 13.2$ g/dl

#### Protocol summary

##### Summary

The objective of our study is to investigate the effect of iron supplementation on hematological indices in pregnant women with hemoglobin more than or equal to 13.2 g/dl. In a randomized, double-blind, placebo-controlled trial eighty-seven pregnant women with Hb $\geq 13.2$  g/dl and ferritin $\geq 14.3$ g/dl were selected with gestational age 13-18 weeks. Each woman received either 50 mg ferrous sulfate daily or placebo during pregnancy. Hb, HCT, MCV, MCH, MCHC, and RBC were measured in 24-28 and 32-36 gestational weeks.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT138710181531N1**  
Registration date: **2009-11-08, 1388/08/17**  
Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2009-11-08, 1388/08/17

##### Registrant information

###### Name

Zeinab Hamzehgardeshi

###### Name of organization / entity

Tarbiat Modarres University

###### Country

Iran (Islamic Republic of)

###### Phone

+98 15 1324 6883

###### Email address

hamzeh@razi.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Tarbiat Modarres University

##### Expected recruitment start date

2002-03-20, 1380/12/29

##### Expected recruitment end date

2003-03-20, 1381/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

A randomized placebo-controlled trial to determine the effect of iron supplementation on hematological indices in pregnant women with hemoglobin  $\geq 13.2$  g/dl

##### Public title

A randomized placebo-controlled trial to determine the effect of iron supplementation on hematological indices in pregnant women with hemoglobin  $\geq 13.2$  g/dl

##### Purpose

Prevention

##### Inclusion/Exclusion criteria

Inclusion criteria: Pregnant women with Hb  $\geq 13.2$  g/dl in the early stage of the second trimester, body mass index (BMI) between 19.8 and 26 kg/m<sup>2</sup>, single pregnancy, age between 17 and 35 years Exclusion criteria: Falling Hb to less than 10.5 g/dl in the second trimester or 11 g/dl in the third trimester, history of any renal, hepatic, thyroid, or cardiac diseases, presence of diabetes, asthma, hypertension, or inflammatory diseases, presence of severe nausea and vomiting of pregnancy, smoking, substance abuse, history of threatened abortion

##### Age

From **17 years** old to **35 years** old

**Gender**

Female

**Phase**

N/A

**Groups that have been masked**

No information

**Sample size**

Target sample size: **87**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Tarbiat Modarres University

**Street address**

Gisha, Jalale Ale Ahmad highway, Tehran.

**City**

Tehran

**Postal code****Approval date**

empty

**Ethics committee reference number**

103/5364

**Health conditions studied****1****Description of health condition studied**

Pregnant women of high hemoglobin

**ICD-10 code**

O28.0

**ICD-10 code description**

Abnormal haematological finding on antenatal screening of mother

**Primary outcomes****1****Description**

Hematologic indices

**Timepoint**

Baseline, at gestational weeks 24 -28 and 32-36

**Method of measurement**

Cell Blood Count with sismex k1000

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Ferrous sulfate, 150 mg tablet with 50 mg ferrous elemental, daily, from 20th gestational week to the end of pregnancy

**Category**

Prevention

**2****Description**

Placebo tablets, one tablet daily, from 20th gestational week to the end of pregnancy

**Category**

Prevention

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Shariati hospital

**Full name of responsible person****Street address**

North Karegar Ave., Tehran

**City**

Tehran

**2****Recruitment center****Name of recruitment center**

Baghiatollah hospital

**Full name of responsible person****Street address**

Wanak, Mollasadra Ave

**City**

Tehran

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Tarbiat Modarres University

**Full name of responsible person**

Vice-chancellor for Research

**Street address**

Gisha, Jalale Ale Ahmad highway, Tehran.

**City**

Tehran

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tarbiat Modarres University

**Proportion provided by this source**

100

**Public or private sector**

empty

**Domestic or foreign origin**

empty

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

empty

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Tarbiat Modarres University, Tehran University  
medical science

**Full name of responsible person**

Zeinab Hamzehgardeshi

**Position**

Ph.D student

**Other areas of specialty/work**

**Street address**

Gisha, Jalale Ale Ahmad highway, Tehran.

**City**

Tehran

**Postal code**

**Phone**

+98 15 1324 6883

**Fax**

**Email**

hamzeh@razi.tums.ac.ir

**Web page address**

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Tarbiat Modarres University, Tehran University of  
Medical Sciences

**Full name of responsible person**

Zeinab Hamzehgardeshi

**Position**

Ph.D student

**Other areas of specialty/work**

**Street address**

Gisha, Jalale Ale Ahmad highway, Tehran.

**City**

Tehran

**Postal code**

**Phone**

+98 15 4324 6883

**Fax**

**Email**

hamzeh@razi.ac.ir

**Web page address**

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Tarbiat modarres University, Tehran University of  
Medical Science

**Full name of responsible person**

Zeinab Hamzehgardeshi

**Position**

Ph.D Student

**Other areas of specialty/work**

**Street address**

Gisha, Jalale Ale Ahmad highway, Tehran.

**City**

Tehran

**Postal code**

**Phone**

+98 15 1324 6883

**Fax**

**Email**

hamzeh@razi.tums.ac.ir

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

empty

**Study Protocol**

empty

**Statistical Analysis Plan**

empty

**Informed Consent Form**

empty

**Clinical Study Report**

empty

**Analytic Code**

empty

**Data Dictionary**

empty